LLY
Eli Lilly and Company
- Revenue, 2025
- $65.2B
- YoY, 2025
- +44.7%
- 5-year CAGR
- +21.6%
- 10-year CAGR
- +12.6%
Revenue
Revenue by fiscal year
| Period | Revenue | YoY |
|---|---|---|
| 2025 | $65.2B | +44.7% |
| 2024 | $45.0B | +32.0% |
| 2023 | $34.1B | +19.6% |
| 2022 | $28.5B | +0.8% |
| 2021 | $28.3B | +15.4% |
| 2020 | $24.5B | +9.9% |
| 2019 | $22.3B | +3.8% |
| 2018 | $21.5B | +7.6% |
| 2017 | $20.0B | −5.9% |
| 2016 | $21.2B | +6.3% |
| 2015 | $20.0B | +1.7% |
| 2014 | $19.6B | −15.1% |
| 2013 | $23.1B | +2.3% |
| 2012 | $22.6B | −6.9% |
| 2011 | $24.3B | +5.2% |
| 2010 | $23.1B | +5.7% |
| 2009 | $21.8B | +7.2% |
| 2008 | $20.4B | +9.3% |
| 2007 | $18.6B | — |